CALR (Calreticulin) variants and mutations
CALR (also known as Calreticulin) is a human protein-coding gene encoding a calreticulin protein. It assists glycoprotein folding and buffers calcium within the endoplasmic reticulum. Somatic frameshift variants create abnormal C termini that activate thrombopoietin-receptor signaling and are major drivers of essential thrombocythemia and primary myelofibrosis. This analysis covers 620 CALR variants and mutations. Of these, 78% have computational variant effect predictions. Disease context includes neoplasm, myeloproliferative disorder, and thrombocythemia 1. Example CALR variants include L2V, L3R, and L3I.
Variant analysis overview
- Gene: CALR
- Protein: Calreticulin
- UniProt accession: P27797
- Organism: Homo sapiens
- Variants analyzed: 620
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 443 unspecified-consequence records; 88 missense variants; 71 synonymous variants; 2 frameshift variants; 4 stop-gained variants; 2 splice-region variants; 3 in-frame deletions; 1 in-frame insertions; 6 substitution
- Prediction scores: 485 variants have prediction scores (78% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: neoplasm, myeloproliferative disorder, thrombocythemia 1, primary myelofibrosis, hemorrhagic disease, neurodegenerative disease, essential thrombocythemia, Alzheimer disease, Parkinson disease, multiple sclerosis, lysosomal storage disease, myelofibrosis.
Protein structure and variant hotspots
- Protein features: 9 binding sites; 5 post-translational modification sites.
- PTM context: 7 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CALR variants
Examples include L2V, L3R, L3I, L3L, S4P, S4S, V5G, V5M. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- L2V (p.Leu2Val), gnomAD 19-12938683-C-G, REVEL 0.10, CADD 22.50
- L3R (p.Leu3Arg), ExAC rs777358098, TOPMed rs777358098, gnomAD rs777358098, REVEL 0.27, CADD 22.40
- L3I (p.Leu3Ile), gnomAD 19-12938686-C-A, REVEL 0.07, CADD 21.30
- L3L (p.Leu3Leu), rs753422007, gnomAD 19-12938688-A-G, CADD 10.70
- S4P (p.Ser4Pro), gnomAD rs1397929746, REVEL 0.03, CADD 17.60
- S4S (p.Ser4Ser), gnomAD 19-12938691-C-A, CADD 9.78
- V5G (p.Val5Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V5M (p.Val5Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V5L (p.Val5Leu), gnomAD 19-12938692-G-T, REVEL 0.08, CADD 16.40
- V5V (p.Val5Val), gnomAD 19-12938694-G-A, CADD 11.80
- P6A (p.Pro6Ala), ExAC rs756694331, TOPMed rs756694331, gnomAD rs756694331, REVEL 0.04, CADD 17.90
- P6L (p.Pro6Leu), ExAC rs780662640, TOPMed rs780662640, gnomAD rs780662640, REVEL 0.07, CADD 20.50, Uncertain significance, not specified
- P6P (p.Pro6Pro), rs747461787, gnomAD 19-12938697-G-A, CADD 14.30
- L7V (p.Leu7Val), gnomAD 19-12938698-C-G, REVEL 0.07, CADD 17.00
- L7L (p.Leu7Leu), rs201581541, gnomAD 19-12938698-C-T, CADD 13.80
- L8V (p.Leu8Val), gnomAD rs941288230, REVEL 0.04, CADD 15.40
- L8L (p.Leu8Leu), gnomAD 19-12938703-G-C, CADD 14.20
- L9F (p.Leu9Phe), gnomAD 19-12938704-C-T, REVEL 0.10, CADD 22.00
- L9L (p.Leu9Leu), rs781690273, gnomAD 19-12938706-C-A, CADD 8.21
- G10C (p.Gly10Cys), gnomAD 19-12938707-G-T, REVEL 0.12, CADD 21.90
- G10R (p.Gly10Arg), gnomAD 19-12938707-G-C, REVEL 0.14, CADD 22.30
- G10G (p.Gly10Gly), rs748461962, gnomAD 19-12938709-C-T, CADD 14.80
- L11F (p.Leu11Phe), ExAC rs770160684, TOPMed rs770160684, gnomAD rs770160684, REVEL 0.06, CADD 17.60
- L11L (p.Leu11Leu), rs368501056, gnomAD 19-12938712-C-T, CADD 9.04
- L12F (p.Leu12Phe), rs763131258, NCI-TCGA Cosmic COSV5713, ExAC rs763131258, gnomAD rs763131258, REVEL 0.04, CADD 11.20, Variant assessed as somatic; moderate impact.
- L12R (p.Leu12Arg), NCI-TCGA TCGA novel, REVEL 0.28, CADD 23.20, Variant assessed as somatic; high impact.
- L12L (p.Leu12Leu), gnomAD 19-12938715-C-G, CADD 4.03
- G13C (p.Gly13Cys), Ensembl rs929780860, REVEL 0.19, CADD 23.30
- G13D (p.Gly13Asp), Ensembl rs1971499887
- G13A (p.Gly13Ala), gnomAD 19-12938714-TC-T, CADD 8.88
- G13G (p.Gly13Gly), rs774405017, gnomAD 19-12938718-C-T, CADD 13.10
- L14L (p.Leu14Leu), rs539393451, gnomAD 19-12938719-C-T, CADD 9.96
- L14V (p.Leu14Val), gnomAD 19-12938719-C-G, REVEL 0.03, CADD 10.60
- A15G (p.Ala15Gly), gnomAD rs1378379005, REVEL 0.05, CADD 11.50
- A15V (p.Ala15Val), gnomAD rs1378379005, REVEL 0.06, CADD 9.89
- A15T (p.Ala15Thr), gnomAD 19-12938722-G-A, REVEL 0.08, CADD 20.70
- A15A (p.Ala15Ala), rs767385998, gnomAD 19-12938724-C-T, CADD 8.07
- V16I (p.Val16Ile), gnomAD rs1176515855, REVEL 0.05, CADD 10.20
- V16F (p.Val16Phe), gnomAD 19-12938725-G-T, REVEL 0.05, CADD 10.40
- A17G (p.Ala17Gly), rs147368353, ClinGen CA9235613, ClinVar RCV004317774, 1000Genomes rs147368353, REVEL 0.22, CADD 15.50, Uncertain significance, not specified
- A17P (p.Ala17Pro), ExAC rs752512916, gnomAD rs752512916
- A17T (p.Ala17Thr), ExAC rs752512916, gnomAD rs752512916, REVEL 0.20, CADD 20.90
- A17V (p.Ala17Val), rs147368353, ClinGen CA9235614, ClinVar RCV004302525, 1000Genomes rs147368353, REVEL 0.12, CADD 14.00, Uncertain significance, not specified
- A17A (p.Ala17Ala), rs1334792849, gnomAD 19-12938730-C-T, CADD 7.42
- E18Q (p.Glu18Gln), TOPMed rs775581620, gnomAD rs775581620, REVEL 0.08, CADD 14.00
- E18K (p.Glu18Lys), gnomAD 19-12938731-G-A, REVEL 0.08, CADD 15.30
- E18D (p.Glu18Asp), gnomAD 19-12938733-G-C, REVEL 0.09, CADD 1.78
- P19L (p.Pro19Leu), gnomAD rs1405396151, REVEL 0.18, CADD 22.70
- P19S (p.Pro19Ser), gnomAD 19-12938734-C-T, REVEL 0.12, CADD 18.50
- P19H (p.Pro19His), gnomAD 19-12938735-C-A, REVEL 0.19, CADD 22.40
- A20S (p.Ala20Ser), gnomAD 19-12938737-G-T, REVEL 0.08, CADD 1.62
- A20V (p.Ala20Val), gnomAD 19-12938738-C-T, REVEL 0.09, CADD 9.46
- A20A (p.Ala20Ala), rs1448200199, gnomAD 19-12938739-C-A, CADD 7.10
- V21I (p.Val21Ile), gnomAD 19-12938740-G-A, REVEL 0.10, CADD 3.72
- V21A (p.Val21Ala), gnomAD 19-12938741-T-C, REVEL 0.22, CADD 23.60
- V21V (p.Val21Val), rs572735736, gnomAD 19-12938742-C-A, CADD 8.44
- Y22H (p.Tyr22His), gnomAD 19-12938743-T-C, REVEL 0.13, CADD 23.40
- Y22Y (p.Tyr22Tyr), gnomAD 19-12938745-C-T, CADD 8.89
- F23L (p.Phe23Leu), gnomAD rs1371775156, REVEL 0.16, CADD 21.40
- F23Y (p.Phe23Tyr), TOPMed rs1971500716
- K24N (p.Lys24Asn), 1000Genomes rs541091872, ExAC rs541091872, gnomAD rs541091872, REVEL 0.11, CADD 23.00
- K24R (p.Lys24Arg), gnomAD rs1223633950, REVEL 0.07, CADD 23.10
- E25E (p.Glu25Glu), rs1313590281, gnomAD 19-12938754-G-A, CADD 14.00
- Q26K (p.Gln26Lys), gnomAD rs1207532147, REVEL 0.12, CADD 21.10
- Q26* (p.Gln26Ter), gnomAD 19-12938755-C-T, CADD 38.00
- Q26R (p.Gln26Arg), gnomAD 19-12938756-A-G, REVEL 0.12, CADD 22.70
- F27L (p.Phe27Leu), gnomAD 19-12938760-T-G, REVEL 0.66, CADD 31.00
- L28L (p.Leu28Leu), rs756852999, gnomAD 19-12938761-C-T, CADD 14.10
- D29N (p.Asp29Asn), gnomAD 19-12938764-G-A, REVEL 0.28, CADD 25.10
- G30A (p.Gly30Ala), gnomAD rs1236351578, REVEL 0.12, CADD 24.10
- G30E (p.Gly30Glu), gnomAD rs1236351578, REVEL 0.21, CADD 27.60
- G30R (p.Gly30Arg), rs1199946705, TOPMed rs1199946705, gnomAD rs1199946705, ClinGen CA404301457, REVEL 0.41, CADD 33.00, Uncertain significance, not specified
- G30* (p.Gly30Ter), gnomAD 19-12938767-G-T, CADD 41.00
- D31G (p.Asp31Gly), 1000Genomes rs146793150, ESP rs146793150, ExAC rs146793150, TOPMed rs146793150, REVEL 0.29, CADD 25.80
- D31V (p.Asp31Val), 1000Genomes rs146793150, ESP rs146793150, ExAC rs146793150, TOPMed rs146793150, REVEL 0.28, CADD 32.00
- D31N (p.Asp31Asn), gnomAD 19-12938770-G-A, REVEL 0.25, CADD 36.00
- D31A (p.Asp31Ala), gnomAD 19-12939134-A-C, REVEL 0.26, CADD 24.40
- D31E (p.Asp31Glu), gnomAD 19-12939135-C-G, REVEL 0.20, CADD 14.50
- D31D (p.Asp31Asp), rs768567178, gnomAD 19-12939135-C-T, CADD 10.10
- G32A (p.Gly32Ala), ESP rs140472880, ExAC rs140472880, TOPMed rs140472880, gnomAD rs140472880, REVEL 0.01, CADD 17.20
- G32E (p.Gly32Glu), ESP rs140472880, ExAC rs140472880, TOPMed rs140472880, gnomAD rs140472880, REVEL 0.02, CADD 19.00
- G32R (p.Gly32Arg), ExAC rs377744854, TOPMed rs377744854, gnomAD rs377744854, REVEL 0.19, CADD 26.50
- G32W (p.Gly32Trp), gnomAD 19-12939136-G-T, REVEL 0.27, CADD 29.70
- G32V (p.Gly32Val), gnomAD 19-12939137-G-T, REVEL 0.15, CADD 23.70
- G32G (p.Gly32Gly), gnomAD 19-12939138-G-C, CADD 12.20
- W33* (p.Trp33Ter), gnomAD 19-12939139-TG-T, CADD 33.00
- W33C (p.Trp33Cys), gnomAD 19-12939141-G-T, REVEL 0.53, CADD 33.00
- T34I (p.Thr34Ile), rs764831280, ClinGen CA404301869, ClinVar RCV004158061, ExAC rs764831280, REVEL 0.06, CADD 22.60, Uncertain significance, not specified
- T34N (p.Thr34Asn), ExAC rs764831280, gnomAD rs764831280, REVEL 0.07, CADD 22.10, Uncertain significance
- T34P (p.Thr34Pro), gnomAD 19-12939142-A-C, REVEL 0.12, CADD 23.20
- T34A (p.Thr34Ala), gnomAD 19-12939142-A-G, REVEL 0.02, CADD 21.90
- T34T (p.Thr34Thr), rs1971509507, gnomAD 19-12939144-T-G, CADD 11.10
- S35A (p.Ser35Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S35S (p.Ser35Ser), rs145899020, gnomAD 19-12939147-C-T, CADD 10.80
- R36S (p.Arg36Ser), gnomAD 19-12939148-C-A, REVEL 0.45, CADD 28.20
- R36C (p.Arg36Cys), gnomAD 19-12939148-C-T, REVEL 0.49, CADD 32.00
- R36H (p.Arg36His), gnomAD 19-12939149-G-A, REVEL 0.52, CADD 28.50
- R36R (p.Arg36Arg), rs1680232676, gnomAD 19-12939150-C-T, CADD 16.30
- W37L (p.Trp37Leu), gnomAD 19-12939152-G-T, REVEL 0.82, CADD 33.00
- W37C (p.Trp37Cys), gnomAD 19-12939153-G-T, REVEL 0.84, CADD 33.00
- I38M (p.Ile38Met), rs546693081, ClinGen CA404302021, ClinVar RCV004434603, Uncertain significance, not specified
- I38F (p.Ile38Phe), gnomAD 19-12939154-A-T, REVEL 0.23, CADD 23.00
- I38I (p.Ile38Ile), rs546693081, gnomAD 19-12939156-C-T, CADD 9.22
- E39K (p.Glu39Lys), gnomAD 19-12939157-G-A, REVEL 0.15, CADD 23.20
- S40S (p.Ser40Ser), gnomAD 19-12939162-C-A, CADD 14.80
- K41N (p.Lys41Asn), gnomAD rs1448209762, REVEL 0.14, CADD 23.60
- K41Q (p.Lys41Gln), gnomAD 19-12939163-A-C, REVEL 0.11, CADD 23.50
- H42L (p.His42Leu), gnomAD rs1285438952, REVEL 0.42, CADD 23.90
- H42Y (p.His42Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- H42H (p.His42His), gnomAD 19-12939168-C-T, CADD 15.40
- K43N (p.Lys43Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K43K (p.Lys43Lys), rs765976100, gnomAD 19-12939171-G-A, CADD 14.60
- S44* (p.Ser44Ter), gnomAD 19-12939173-C-A, CADD 38.00
- D45G (p.Asp45Gly), ExAC rs753324324, TOPMed rs753324324, gnomAD rs753324324, REVEL 0.56, CADD 32.00
- D45V (p.Asp45Val), ExAC rs753324324, TOPMed rs753324324, gnomAD rs753324324, REVEL 0.55, CADD 26.70
- F46L (p.Phe46Leu), gnomAD 19-12939178-T-C, REVEL 0.08, CADD 23.50
- G47S (p.Gly47Ser), gnomAD 19-12939181-G-A, REVEL 0.83, CADD 33.00
- G47G (p.Gly47Gly), gnomAD 19-12939183-C-A, CADD 13.30
- K48E (p.Lys48Glu), gnomAD 19-12939184-A-G, REVEL 0.19, CADD 22.90
- K48Q (p.Lys48Gln), gnomAD 19-12939184-A-C, REVEL 0.12, CADD 23.00
- K48K (p.Lys48Lys), gnomAD 19-12939186-A-G, CADD 15.80
- F49Y (p.Phe49Tyr), Ensembl rs1971509806
- V50F (p.Val50Phe), ExAC rs764612484, TOPMed rs764612484, gnomAD rs764612484, REVEL 0.11, CADD 23.00, Uncertain significance
- V50I (p.Val50Ile), ExAC rs764612484, TOPMed rs764612484, gnomAD rs764612484, Uncertain significance
- V50L (p.Val50Leu), rs764612484, ClinGen CA9235659, ClinVar RCV004203084, ExAC rs764612484, REVEL 0.07, CADD 18.30, Uncertain significance, not specified
- L51R (p.Leu51Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L51V (p.Leu51Val), rs1315949624, NCI-TCGA Cosmic COSV5711, gnomAD rs1315949624, REVEL 0.12, CADD 21.90, Variant assessed as somatic; moderate impact.
- L51I (p.Leu51Ile), gnomAD 19-12939193-C-A, REVEL 0.12, CADD 22.20
- L51L (p.Leu51Leu), gnomAD 19-12939195-C-A, CADD 6.98
- S52N (p.Ser52Asn), gnomAD rs1282502862
- S52R (p.Ser52Arg), gnomAD rs1971509989, REVEL 0.29, CADD 27.00
- S52T (p.Ser52Thr), gnomAD rs1282502862
- S52S (p.Ser52Ser), rs1446622339, gnomAD 19-12939198-T-C, CADD 15.90
- S53F (p.Ser53Phe), TOPMed rs1971510139, gnomAD rs1971510139, REVEL 0.32, CADD 32.00
- S53Y (p.Ser53Tyr), TOPMed rs1971510139, gnomAD rs1971510139, REVEL 0.17, CADD 25.20, Uncertain significance, not specified
- S53S (p.Ser53Ser), rs1277520418, gnomAD 19-12939201-C-T, CADD 12.50
- G54C (p.Gly54Cys), gnomAD 19-12939202-G-T, REVEL 0.81, CADD 33.00
- G54D (p.Gly54Asp), gnomAD 19-12939203-G-A, REVEL 0.76, CADD 32.00
- G54A (p.Gly54Ala), gnomAD 19-12939203-G-C, REVEL 0.60, CADD 31.00
- G54G (p.Gly54Gly), gnomAD 19-12939204-C-G, CADD 15.50
- K55E (p.Lys55Glu), TOPMed rs1971510253, gnomAD rs1971510253, REVEL 0.31, CADD 25.50
- K55R (p.Lys55Arg), gnomAD 19-12939206-A-G, REVEL 0.29, CADD 25.00
- F56L (p.Phe56Leu), ExAC rs757608389, gnomAD rs757608389, REVEL 0.26, CADD 23.60
- Y57* (p.Tyr57Ter), 1000Genomes rs200631709, ExAC rs200631709, gnomAD rs200631709, CADD 35.00
- Y57C (p.Tyr57Cys), rs138503495, ClinGen CA9235662, ClinVar RCV000943310, ESP rs138503495, REVEL 0.47, CADD 32.00, Benign, not provided
- Y57H (p.Tyr57His), gnomAD 19-12939211-T-C, REVEL 0.37, CADD 24.60
- Y57Y (p.Tyr57Tyr), rs200631709, gnomAD 19-12939213-C-T, CADD 13.10
- G58R (p.Gly58Arg), ExAC rs758537042, gnomAD rs758537042
- G58S (p.Gly58Ser), gnomAD 19-12939214-G-A, REVEL 0.24, CADD 25.30
- G58D (p.Gly58Asp), gnomAD 19-12939215-G-A, REVEL 0.22, CADD 24.80
- D59N (p.Asp59Asn), ExAC rs780108025, TOPMed rs780108025, gnomAD rs780108025, REVEL 0.43, CADD 29.60
- D59G (p.Asp59Gly), gnomAD 19-12939218-A-G, REVEL 0.42, CADD 27.40
- D59E (p.Asp59Glu), gnomAD 19-12939219-C-G, REVEL 0.21, CADD 22.90
- D59D (p.Asp59Asp), rs76337616, gnomAD 19-12939219-C-T, CADD 13.80
- E60D (p.Glu60Asp), 1000Genomes rs550300014, ExAC rs550300014, gnomAD rs550300014, REVEL 0.06, CADD 22.30
- E60K (p.Glu60Lys), gnomAD 19-12939220-G-A, REVEL 0.02, CADD 19.80
- E60E (p.Glu60Glu), rs550300014, gnomAD 19-12939222-G-A, CADD 14.30
- E61Q (p.Glu61Gln), gnomAD 19-12939223-G-C, REVEL 0.26, CADD 26.90
- K62E (p.Lys62Glu), gnomAD rs1383867644, REVEL 0.14, CADD 23.70
- K62N (p.Lys62Asn), NCI-TCGA Cosmic COSV5712, Variant assessed as somatic; moderate impact.
- K62R (p.Lys62Arg), NCI-TCGA Cosmic COSV5712, Variant assessed as somatic; moderate impact.
- K62K (p.Lys62Lys), rs1414627392, gnomAD 19-12939228-A-G, CADD 14.50
- D63N (p.Asp63Asn), gnomAD rs1335654763, REVEL 0.49, CADD 32.00
- D63G (p.Asp63Gly), gnomAD 19-12939230-A-G, REVEL 0.79, CADD 33.00
- K64I (p.Lys64Ile), gnomAD 19-12939233-A-T, REVEL 0.38, CADD 33.00
- G65C (p.Gly65Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L66L (p.Leu66Leu), gnomAD 19-12939430-T-C, CADD 14.30
- Q67* (p.Gln67Ter), Ensembl rs765669613, CADD 40.00
- Q67H (p.Gln67His), NCI-TCGA Cosmic COSV5713, REVEL 0.38, CADD 24.70, Variant assessed as somatic; moderate impact.
- Q67R (p.Gln67Arg), TOPMed rs1274707844, REVEL 0.38, CADD 25.10
- T68A (p.Thr68Ala), gnomAD 19-12939436-A-G, REVEL 0.63, CADD 31.00
- T68T (p.Thr68Thr), gnomAD 19-12939438-A-C, CADD 6.73
- S69N (p.Ser69Asn), gnomAD 19-12939440-G-A, REVEL 0.25, CADD 25.70
- S69S (p.Ser69Ser), gnomAD 19-12939441-C-T, CADD 16.10
- Q70* (p.Gln70Ter), gnomAD 19-12939442-C-T, CADD 38.00
- D71G (p.Asp71Gly), gnomAD rs1404498335, REVEL 0.53, CADD 29.50
- D71N (p.Asp71Asn), gnomAD 19-12939445-G-A, REVEL 0.19, CADD 24.60
- A72T (p.Ala72Thr), TOPMed rs1228790764, gnomAD rs1228790764, REVEL 0.55, CADD 31.00
- A72V (p.Ala72Val), gnomAD rs1278938364, REVEL 0.55, CADD 25.30
- A72A (p.Ala72Ala), gnomAD 19-12939450-A-G, CADD 16.80
Public CALR analysis runs
- CALR analysis run — CALR (620 variants) — completed 2026-08-18